Hyundai Bioscience Balance Sheet Health
Financial Health criteria checks 6/6
Hyundai Bioscience has a total shareholder equity of ₩45.3B and total debt of ₩5.4B, which brings its debt-to-equity ratio to 11.9%. Its total assets and total liabilities are ₩52.8B and ₩7.5B respectively.
Key information
11.9%
Debt to equity ratio
₩5.40b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩11.81b |
| Equity | ₩45.27b |
| Total liabilities | ₩7.52b |
| Total assets | ₩52.79b |
Recent financial health updates
Recent updates
The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About
Mar 14
Is Hyundai Bioscience (KOSDAQ:048410) Using Too Much Debt?
Feb 07
Imagine Holding Hyundai Bioscience (KOSDAQ:048410) Shares While The Price Zoomed 439% Higher
Jan 03The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About
Nov 29Financial Position Analysis
Short Term Liabilities: A048410's short term assets (₩15.2B) exceed its short term liabilities (₩6.9B).
Long Term Liabilities: A048410's short term assets (₩15.2B) exceed its long term liabilities (₩574.0M).
Debt to Equity History and Analysis
Debt Level: A048410 has more cash than its total debt.
Reducing Debt: A048410's debt to equity ratio has reduced from 22.3% to 11.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A048410 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A048410 has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 29.6% each year.